AZD9668
Phase 2Small molecule
AstraZenecaAZD9668 is one of 122 small molecule programs targeting Bronchiectasis. It is currently in Phase 2.
4
Indications
12
Total Trials
0
Active Trials
121
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Jardiance
Boehringer IngelheimPreclinical
AZD9668
AstraZenecaPhase 2
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Forxiga
AstraZenecaPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Antiplatelet Drug
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preclinical
Sglt2i
UUniversity of Chicago
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease3 trials
Intravenous1 trial
Cystic Fibrosis1 trial
Efficacy and Safety1 trial
4 more indications
Bronchiectasis1 trial
Type 2 Diabetes1 trial
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
Completed·—·Phase 2·NCT02597101·14 enrolled
Interaction1 trial
Unspecified2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD9668. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company